Incyte Co. (INCY) Director Sells $7,436,000.00 in Stock

Incyte Co. (NASDAQ:INCY) Director Paul A. Friedman sold 50,000 shares of Incyte stock in a transaction on Friday, March 17th. The stock was sold at an average price of $148.72, for a total transaction of $7,436,000.00. Following the completion of the transaction, the director now directly owns 302,976 shares in the company, valued at $45,058,590.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Incyte Co. (NASDAQ:INCY) traded up 0.38% during mid-day trading on Monday, hitting $148.52. 1,744,105 shares of the stock were exchanged. The stock’s 50 day moving average is $129.91 and its 200 day moving average is $105.70. The firm has a market cap of $28.13 billion, a P/E ratio of 275.04 and a beta of 0.78. Incyte Co. has a 12 month low of $62.63 and a 12 month high of $153.15.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, February 14th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by $0.08. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The company had revenue of $326 million for the quarter, compared to analysts’ expectations of $324.90 million. During the same quarter in the previous year, the company posted $0.29 EPS. The business’s quarterly revenue was up 33.9% on a year-over-year basis. Analysts expect that Incyte Co. will post $0.39 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

var userip;Your IP Address: document.write(userip);

Hedge funds have recently added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. raised its stake in Incyte by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 22 shares during the last quarter. Toronto Dominion Bank raised its stake in Incyte by 57.3% in the third quarter. Toronto Dominion Bank now owns 1,457 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 531 shares during the last quarter. Seven Bridges Advisors LLC raised its stake in Incyte by 27.1% in the third quarter. Seven Bridges Advisors LLC now owns 1,867 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 398 shares during the last quarter. Pinnacle Associates Ltd. bought a new stake in Incyte during the fourth quarter valued at $212,000. Finally, IFM Investors Pty Ltd bought a new stake in Incyte during the fourth quarter valued at $214,000. Institutional investors own 92.62% of the company’s stock.

Several analysts recently weighed in on INCY shares. JMP Securities reiterated an “outperform” rating and issued a $130.00 price target on shares of Incyte in a report on Wednesday, January 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $149.00 price target (up previously from $135.00) on shares of Incyte in a report on Thursday, February 16th. Vetr upgraded shares of Incyte from a “buy” rating to a “strong-buy” rating and set a $133.50 price target on the stock in a report on Monday, January 30th. Credit Suisse Group AG started coverage on shares of Incyte in a report on Monday, January 23rd. They issued an “outperform” rating and a $137.00 price target on the stock. Finally, Cowen and Company reiterated an “outperform” rating on shares of Incyte in a report on Wednesday, March 8th. One analyst has rated the stock with a sell rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $122.86.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

5 Day Chart for NASDAQ:INCY

Receive News & Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition


© 2006-2017 Ticker Report. Google+.